Audentes Therapeutics (BOLD) Gets a Buy Rating from Chardan Capital

In a report released yesterday, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLDResearch Report), with a price target of $60.00. The company’s shares closed last Monday at $28.61.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 22.9% and a 52.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Rocket Pharmaceuticals, and Axovant Gene Therapies.

Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $41.33, a 40.1% upside from current levels. In a report issued on November 19, Evercore ISI also upgraded the stock to Buy with a $40.00 price target.

See today’s analyst top recommended stocks >>

Based on Audentes Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $45.74 million. In comparison, last year the company had a GAAP net loss of $36.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.